News

The SEQUOIA-HCM trial presents aficamten as a promising treatment for symptomatic obstructive hypertrophic cardiomyopathy, showing significant improvements in multiple endpoints.

Nieca Goldberg, MD, discusses important news and updates in cardiovascular health among women from the early portions of 2024.

The analysis of NHANES data revealed almost 90% of adults meet the criteria for stage 1 or greater CKM syndrome, consistent from 2011-2020.

Sibille and colleagues have made progress in refining the therapeutic pathways of Alzheimer disease. Human trials may soon follow.

Factors, including social deprivation and race, significantly affected visit adherence for patients with nAMD across a large healthcare system.

This discussion covered the topic of e-cigarette use and its potential treatment with cytisinicline, a plant-based medication which may aid vapers in quitting.

Phillips emphasizes the importance of screening for obsessive-compulsive disorders, such as OCD, body dysmorphic disorder, and trichillomania.

A novel score based on a combination of cytokeratins and routine laboratory tests provided a more accurate diagnosis of HCC versus serum α-fetoprotein alone.

At ARVO 2024, Nazlee Zebardast, MD, MSc describes the value of a polygenic risk score to predict the onset of primary open-angle glaucoma.

In an interview with HCPLive, Jha said clinicians should think of interventional approaches for treatment-resistant depression “sooner rather than later.”

McIntyre discusses how GLP-1 and GIP receptor agonists like semaglutide could potentially improve both acute and long-term measures of psychiatric disease.

Glecaprevir/pibrentasvir is an effective treatment for HCV with high rates of SVR, even in patients with cirrhosis undergoing a shorter treatment regimen.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

In an interview, Phillip explained the difference between OCD and body dysmorphic disorder, even though they are grouped in the DSM-5.

A higher dietary intake of several nutrients was strongly associated with slower progression toward the central macula in eyes with non-central GA.

These data suggest that a multidisciplinary clinic approach results in several benefits including reduced risk of cardiovascular events among those with psoriasis.

This clinical quiz will test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America Hepatitis C guideline.

At ARVO 2024, Roger Goldberg, MD explores the greater reductions in hard exudates achieved with faricimab than aflibercept in eyes with DME.

This analysis was designed to look into the timing and specific elements which mediate the relationship between eczema and systemic antibiotic use.

In an interview with HCPLive, Barnett discussed the ethical concerns of using psychedelics for treating substance use disorders.

Results suggest chronic hepatitis B virus is globally underassessed and undertreated, especially among women and Asian minorities in the West.

In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when they have comorbidities.

At ARVO 2024, Deepayan Kar, MD, PhD, describes the potential of measuring contrast sensitivity function using a novel gaze tracking-based VR headset in AMD.

The latest guidance on hypertrophic cardiomyopathy contain new endorsements for the cardiac myosin inhibitor class and other aspects of management.

These data highlight the safety, efficacy, and long-term disease control results of treatment with topical ruxolitinib for a subpopulation of adolescents with atopic dermatitis.

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

Sofosbuvir/velpatasvir/voxilaprevir rescue therapy was safe and effective, and SVR did not significantly differ based on genotype, cirrhosis, or first-line therapy.

Dolly Chang, MD, PhD, describes results from an exploratory analysis on the long-term impact of rapid fluid reduction on outcomes in DME.